Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has eight programs in various stages of research and development, with five in clinical development. The lead clinical program is elagolix for endometriosis. The company relies heavily on collaborations with pharmaceutical companies (e.g., Dainippon Sumitomo Pharma, GlaxoSmithKline) for funding and development.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 | Balance Sheet (Sep 30, 2008) |
|---|---|---|---|
| Total Revenues | $761 | $3,246 | - |
| Net Loss | $(17,711) | $(59,759) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.46) | $(1.56) | - |
| Operating Expenses | $(16,465) | $(59,829) | - |
| Cash and Cash Equivalents | - | - | $80,125 |
| Total Investments (Short & Long Term) | - | - | $38,079 |
| Total Assets | - | - | $207,733 |
| Total Liabilities | - | - | $144,086 |
| Stockholders' Equity | - | - | $63,647 |
Liquidity: Cash, cash equivalents, and investments totaled $118.2 million as of September 30, 2008. Management believes existing resources are sufficient for at least the next 12 months.
Debt: The company has a significant "Leaseback financing obligation" of $108.7 million and a current portion of long-term debt of $276 thousand.
Material Changes vs. Prior Period
- Revenue Increase: Revenues for the nine months ended September 30, 2008, increased to $3.2 million from $0.7 million in the prior year period. This was driven by a $1.0 million milestone payment from GSK and $2.2 million in amortized licensing fees from Dainippon Sumitomo Pharma.
- Expense Reduction: Operating expenses decreased significantly due to a restructuring program initiated in December 2007.
- R&D Expenses: Decreased to $43.4 million (9 months 2008) from $57.6 million (9 months 2007), primarily due to reduced personnel costs ($9.0 million savings) and lower external development costs.
- G&A Expenses: Decreased to $16.4 million (9 months 2008) from $26.7 million (9 months 2007), despite a $2.0 million net restructuring charge in the current period.
- Net Loss Improvement: Net loss for the nine months ended September 30, 2008, was $59.8 million, a decrease from $79.3 million in the same period in 2007.
- Investment Portfolio: The company holds $22.6 million (par value) of auction rate securities (ARS). Due to global credit market liquidity issues, these securities are currently illiquid. The company recorded a realized loss of $0.7 million and an unrealized loss of $0.6 million related to these assets.
Outlook, Risks, and Contingencies
- Restructuring and Relocation: The company expects the December 2007 restructuring to reduce annual expenses by approximately $19.0 million. In Q4 2008, the company plans to consolidate operations into one building, which will trigger a "cease-use date" and a corresponding charge for remaining lease rentals on the vacated building.
- Indiplon Uncertainty: The future of the product candidate indiplon is uncertain. Following a 2007 FDA "Approvable Letter" that required additional studies, the company ceased U.S. clinical development. Refiling the NDA would require significant resources and time, with no guarantee of approval.
- Liquidity of Investments: The company faces liquidity risk regarding its $22.6 million portfolio of auction rate securities. While they continue to pay interest, they cannot be sold without potential loss of principal until auctions succeed or they mature. UBS has offered a program allowing the company to sell these securities at par value between June 2010 and July 2012.
- Legal Proceedings: A consolidated securities class action lawsuit regarding indiplon statements was dismissed by the court in September 2008, but plaintiffs have elected to stand on the complaint and may appeal. A shareholder derivative suit is stayed pending the outcome of the class action.
- Future Funding: The company expects to incur operating losses for the foreseeable future and may require additional funding through strategic alliances or equity/debt offerings to continue development programs.
Key Facts for Investor Verification
- Illiquid Assets: Verify the status of the $22.6 million in auction rate securities and the timeline for the UBS ARS Rights program (exercise period June 2010–July 2012).
- Indiplon Status: Confirm if the company intends to pursue the additional FDA requirements for indiplon or if the program remains on hold.
- Restructuring Charges: Monitor the Q4 2008 financial statements for the specific charge related to the office consolidation and "cease-use date" accounting.
- Cash Burn Rate: Assess whether the $118.2 million in liquid assets is sufficient to fund operations through the next 12 months given the ongoing R&D costs and potential legal expenses.
- Collaboration Revenue: Track the timing of future milestone payments from partners like GSK and Dainippon Sumitomo Pharma, as these are critical to revenue recognition.